* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Debt-to-Revenue Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
SHSE:600332 vs MCK, COR, CAH: Debt-to-Revenue Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Debt-to-Revenue vs Medical Distribution Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data,
the Revenue data used here is four times the quarterly (Mar. 2026) Revenue data.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) has a Debt-to-Revenue of 0.20 as of Mar. 2026.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Debt-to-Revenue too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Debt-to-Revenue is 0.20. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Debt-to-Revenue compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Debt-to-Revenue of 0.20 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Revenue for a Medical Distribution company?
A good Debt-to-Revenue depends on the Medical Distribution industry context. However, Debt-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Revenue mean?
A high Debt-to-Revenue can signal that a stock is expensive relative to its fundamentals. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Debt-to-Revenue is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥29.35, compared to a current price of ¥20.67 — trading 29.6% below its estimated fair value. The current Debt-to-Revenue is 0.20. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Revenue calculated?
Debt-to-Revenue is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332), the current Debt-to-Revenue is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (SHSE:600332) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of ¥20.67 is trading 29.6% below its estimated GF Value™ of ¥29.35.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for SHSE:600332:
Debt-to-Revenue: 0.20
GF Value™: ¥29.35 vs. price of ¥20.67 (29.6% below fair value)
No single metric tells the full story. See the SHSE:600332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
67GF Score
Get the complete analysis for SHSE:600332
Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600332 has been successfully added to your 
